Crinetics Pharmaceuticals, Inc.
CRNX
$35.20
$0.732.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -298.41M | -277.91M | -258.54M | -235.46M | -214.53M |
| Total Depreciation and Amortization | 2.79M | 2.26M | 1.76M | 1.29M | 1.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.02M | 55.60M | 51.20M | 44.31M | 39.08M |
| Change in Net Operating Assets | 11.64M | 20.24M | 27.25M | 11.42M | 8.04M |
| Cash from Operations | -225.97M | -199.81M | -178.33M | -178.45M | -166.31M |
| Capital Expenditure | -3.84M | -3.75M | -6.72M | -6.00M | -4.69M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -570.97M | -116.29M | -327.21M | -242.86M | -195.73M |
| Cash from Investing | -574.82M | -120.04M | -333.94M | -248.86M | -200.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.06B | 512.56M | 813.05M | 820.58M | 411.68M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -49.44M | -18.24M | -38.18M | -38.55M | -22.74M |
| Cash from Financing | 1.01B | 494.32M | 774.87M | 782.03M | 388.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 209.65M | 174.47M | 262.61M | 354.73M | 22.22M |
